‘Building Better Mice’ Is the Goal of a New NCI Consortium

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

BETHESDA, Md--Forget about a better mousetrap, the National Cancer Institute wants to build better mice.

BETHESDA, Md--Forget about a better mousetrap, the National Cancer Institute wants to build better mice.

The Institute plans to fund the "Mouse Models for Human Cancer Consortium," consisting of up to six research teams with the necessary scientific and technical expertise to develop new mouse strains or improve existing mouse strains for cancer research.

The aim is to seek new animal models "to test current and future therapeutic or prevention strategies, or for early detection or diagnostic imaging," Cheryl Marks, PhD, of the NCI’s Division of Cancer Biology told the National Cancer Advisory Board.

The NCI expects to solicit and review applications, and have the consortium up and running in the spring of 1999. The consortium concept aims to encourage teams "to pursue their most innovative ideas and to implement new technologies" and to "stimulate interactions among the teams in the consortium, the NCI, and the cancer research community," Dr. Marks said.

The mouse models consortium is the first major recommendation from NCI’s Preclinical Models for Cancer Working Group. NCI is currently pursuing how best to implement other recommendations from the working group.

Recent Videos
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
2 experts are featured in this series.
Related Content